ClinicalTrials.gg
CompletedNCT02171507Updated Jun 24, 2014

Relative Bioavailability of Dabigatran and Diclofenac After Dabigatran Etexilate and Diclofenac Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers

A Phase 1 interventional study of Dabigatran etexilate and Diclofenac in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-24.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To investigate the relative bioavailability of dabigatran with and without concomitant administration of diclofenac and the relative bioavailability of diclofenac with and without concomitant administration of dabigatran etexilate

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12-lead , clinical laboratory tests
  2. Age ≥18 and ≤55 years
  3. (BMI) ≥18.5 and BMI ≤29.9 kg/m2
  4. Signed and dated written prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation

Exclusion criteria

Exclusion criteria:

  1. gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Relevant surgery of gastrointestinal tract
  3. History of any bleeding disorder including history of gastrointestinal erosions and ulcer or acute blood coagulation defect
  4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  5. History of relevant orthostatic hypotension, fainting spells or blackouts
  6. Chronic or relevant acute infections
  7. History of allergy/ (including drug allergy) which is deemed relevant to the objectives of the trial as judged by the investigator
  8. Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  9. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  10. Participation in another trial with an drug within two months prior to administration or during the trial
  11. Alcohol abuse (more than 60 g/day)
  12. Drug abuse
  13. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  14. Excessive physical activities (within one week prior to administration or during the trial)
  15. Any laboratory value outside the reference range that is of clinical relevance
  16. Subjects with abnormal counts and any relevant deviation in the assessment of platelet function (PFA test) must be excluded
  17. Inability to comply with dietary regimen of study centre
  18. Females of child bearing potential who are pregnant, breast feeding or who are either not surgically sterile or are sexually active and not using an acceptable form of as either the oral contraceptives since at least two months and the double barrier method, i.e. intrauterine device with spermicide and condom for the male partner
  19. Male subjects must agree to minimize the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the post study medical examination. Acceptable methods of contraception comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two month)
  20. Planned surgeries within four weeks following the end-of study examination
  21. Intake of medication, which influences the blood clotting, i.e., acetylsalicylic acid, cumarin etc.
  22. The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
  23. Vulnerable subjects (e.g. persons kept in detention).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Dabigatran etexilate

    Drug: Dabigatran etexilate

  • Active comparator
    Diclofenac

    Drug: Diclofenac

  • Experimental
    Dabigatran etexilate + diclofenac

    Drug: Dabigatran etexilate · Drug: Diclofenac

Interventions

06

What researchers measure

Primary outcomes

  1. AUCτ,ss on Day 4 (area under the concentration-time curve of dabigatran in plasma at steady state over one dosing interval)

    Time frame: from pre-dose up to 72 hours post-dose

  2. Cmax,ss (maximum concentration of dabigatran in plasma at steady state)

    Time frame: from pre-dose up to 72 hours post-dose

  3. Cmax (maximal concentration of diclofenac in plasma)

    Time frame: from pre-dose up to 72 hours post-dose

  4. AUC0-infinity (area under the concentration-time curve of diclofenac in plasma extrapolated to infinity)

    Time frame: from pre-dose up to 72 hours post-dose

  5. aPTT (activated partial thromboplastin time) and ECT (Ecarin clotting time) with and without diclofenac

    Time frame: from pre-dose up to 72 hours post-dose

  6. AUERτ,ss (area under the effect ratio-time curve of dabigatran in plasma at steady state over a uniform dosing interval τ)

    Time frame: from pre-dose up to 72 hours post-dose

  7. ERmax,ss (maximal effect ratio of dabigatran in plasma at steady state)

    Time frame: from pre-dose up to 72 hours post-dose

Secondary outcomes

  1. AUC0-tz,ss (area under the concentration-time curve of dabigatran in plasma from the time point 0 after the last dose at steady state to the last quantifiable dabigatran plasma concentration within the uniform dosing interval τ)

    Time frame: from pre-dose up to 72 hours post-dose

  2. tz,ss (time of last measurable concentration of dabigatran in plasma within the dosing interval τ at steady state)

    Time frame: from pre-dose up to 72 hours post-dose

  3. tmax,ss (time from last dosing to the maximum concentration of dabigatran in plasma at steady state on Day 4)

    Time frame: from pre-dose up to 72 hours post-dose

  4. CL/Fss (apparent clearance of dabigatran in the plasma at steady state after extravascular multiple dose administration)

    Time frame: from pre-dose up to 72 hours post-dose

  5. CLR,ss (renal clearance of dabigatran at steady state determined over the dosing interval τ)

    Time frame: from pre-dose up to 72 hours post-dose

  6. C min,ss (minimum measured concentration of dabigatran in plasma at steady state over a uniform dosing interval τ)

    Time frame: from pre-dose up to 72 hours post-dose

  7. tmin,ss (time from last dosing to the minimum concentration of dabigatran in plasma at steady state over a uniform dosing interval τ)

    Time frame: from pre-dose up to 72 hours post-dose

  8. Cpre,ss (pre-dose concentration of dabigatran in plasma at steady state immediately before administration of the next dose)

    Time frame: from pre-dose up to 72 hours post-dose

  9. MRTp.o.,ss (mean residence time of dabigatran in the body at steady state after oral administration)

    Time frame: from pre-dose up to 72 hours post-dose

  10. Vz/Fss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration)

    Time frame: from pre-dose up to 72 hours post-dose

  11. Aeτ,ss (amount of dabigatran that is eliminated in urine at steady state over a uniform dosing interval τ)

    Time frame: 0 to 12 h and 12 to 24 h after administration on day 4

  12. feτ,ss (fraction of parent drug eliminated in urine at steady state over a uniform dosing interval τ)

    Time frame: 0 to 12 h and 12 to 24 h after administration on day 4

  13. AUC0-tz (area under the concentration-time curve of diclofenac and 4´- hydroxydiclofenac in plasma over the time interval 0 to the last quantifiable analyte plasma concentration after single dose administration)

    Time frame: from pre-dose up to 72 hours post-dose

  14. tz (time of last measurable concentration of diclofenac and 4´- hydroxydiclofenac in plasma following a single dose)

    Time frame: from pre-dose up to 72 hours post-dose

  15. %AUCtz-infinity (percentage of the AUC0-infinity that is obtained by extrapolation) for diclofenac and 4´- hydroxydiclofenac

    Time frame: from pre-dose up to 72 hours post-dose

  16. tmax (time from dosing to the maximum concentration of diclofenac and 4´- hydroxydiclofenac in plasma following a single dose)

    Time frame: from pre-dose up to 72 hours post-dose

  17. λz (terminal rate constant in plasma after a single dose) for diclofenac and 4´- hydroxydiclofenac

    Time frame: from pre-dose up to 72 hours post-dose

  18. t1/2 (terminal half-life of diclofenac and 4´- hydroxydiclofenac in plasma after a single dose)

    Time frame: from pre-dose up to 72 hours post-dose

  19. MRTp.o. (mean residence time of diclofenac and 4´- hydroxydiclofenac in the body after single dose oral administration)

    Time frame: from pre-dose up to 72 hours post-dose

  20. CL/F (apparent clearance of diclofenac and 4´- hydroxydiclofenac in the plasma after extravascular single dose administration)

    Time frame: from pre-dose up to 72 hours post-dose

  21. Vz/F (apparent volume of distribution during the terminal phase λz following extravascular dose) for diclofenac and 4´- hydroxydiclofenac

    Time frame: from pre-dose up to 72 hours post-dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006 and a primary completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 24, 2014
Start
May 2006
Primary completionActual
Jul 2006
Last update
Jun 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02171507
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
May 2006
Primary completion
Jul 2006
Last update
Jun 24, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dabigatran · Diclofenac

Start the discussion